Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2023 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea präsentiert nach erfolgreich implementierter neuer Strategie starke Finanzergebnisse für 2022

22 % höhere Lizenzeinnahmen (Royalties) für Antipilzmedikament Cresemba®Betriebsgewinn in Höhe von CHF 18.5 Mio. und CHF 12.1 Mio. Konzerngewinn Verbesserte Bilanzstruktur nach nicht-verwässernder...
February 14, 2023 01:15 ET | Source: Basilea Pharmaceutica AG

Basilea reports strong financial results 2022 based on successful implementation of new strategy

22% year-on-year increase of royalty income from antifungal Cresemba®Operating profit of CHF 18.5 million and net profit of CHF 12.1 millionStrengthened balance sheet through non-dilutive repayment of...
February 10, 2023 08:45 ET | Source: Chibougamau Independent Mines Inc.

Chibougamau annonce l’octroi d’options d’achat d’actions

ROUYN-NORANDA, Québec, 10 févr. 2023 (GLOBE NEWSWIRE) -- MINES INDÉPENDANTES CHIBOUGAMAU INC. (CBG-V – Bourse de Croissance TSX au Canada, CLL1 – Bourses de Francfort, Berlin, Stuttgart et...
February 10, 2023 08:45 ET | Source: Chibougamau Independent Mines Inc.

Chibougamau Announces Stock Option Grant

ROUYN-NORANDA, Quebec, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Chibougamau Independent Mines Inc. (CBG-TSX-V in Canada, CLL1-Frankfurt, Stuttgart, Berlin and Lang & Schwarz Stock Exchanges in Germany,...
February 07, 2023 01:29 ET | Source: Basilea Pharmaceutica AG

Fortgesetzt gute Cresemba® (Isavuconazol)-Verkaufszahlen in der Region Asien-Pazifik und China lösen zweite Umsatzmeilensteinzahlung von Pfizer an Basilea aus

Basel/Allschwil, 07. Februar 2023Basilea Pharmaceutica AG (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren...
February 07, 2023 01:29 ET | Source: Basilea Pharmaceutica AG

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer

Basel/Allschwil, Switzerland, February 07, 2023Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and...
February 06, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in February-March

BIO CEO & Investor Conference 2023 IASLC 2023 Targeted Therapies of Lung Cancer Meeting 16th Annual European Life Sciences CEO ForumCancer Epigenetics Institute Symposium: From Genes to Chromatin...
February 03, 2023 18:00 ET | Source: Valour Inc.

Valour Inc. Announces Change of Auditor

TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Valour Inc. (the “Company” or “Valour”) (NEO: DEFI) (GR: RMJR) (OTCQB: DEFTF), a technology company bridging the gap between traditional capital markets...
February 02, 2023 01:00 ET | Source: Compagnie Financière Tradition

Compagnie Financière Tradition: Adjusted revenue of CHF 1,028.6m in 2022, growth of 10.6% in constant currencies

Ad hoc announcement pursuant to Article 53 of the Six Exchange Regulation Listing Rules Lausanne, 2 February 2023 Adjusted revenue of CHF 1,028.6m in 2022, growth of 10.6% in constant...
February 02, 2023 01:00 ET | Source: Compagnie Financière Tradition

Compagnie Financière Tradition: Adjusted revenue of CHF 1,028.6m in 2022, growth of 10.6% in constant currencies

Ad hoc announcement pursuant to Article 53 of the Six ExchangeRegulation Listing Rules Lausanne, 2 February 20213 Adjusted revenue of CHF 1,028.6m in 2022, growth of 10.6% in constant...